Comorbidities in Patients with Psoriasis

American Journal of Medicine

Volumn 122, Issue 12, 2009, Pages

  Gottlieb, Alice B ^a   Dann, Frank ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Cardiovascular disease; Metabolic syndrome; Psoriasis; Psoriatic arthritis comorbidities

Indexed keywords

ARSENIC DERIVATIVE; AZATHIOPRINE; CYCLOSPORIN; METHOTREXATE; PSORALEN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; COMORBIDITY; CUTANEOUS T CELL LYMPHOMA; DEPRESSION; DYSLIPIDEMIA; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RISK FACTOR; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; DERMATOLOGIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METHOTREXATE; NEOPLASMS; OBESITY; PSORIASIS;

EID: 72049101867     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.06.021     Document Type: Article

References (104)

1. Gottlieb A.B., Chao C., and Dann F. Psoriasis comorbidities. J Dermatolog Treat 19 (2008) 5-21
2. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113 (2004) 1664-1675
3. Myers W.A., Gottlieb A.B., and Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24 (2006) 438-447
4. Langley R.G., Krueger G.G., and Griffiths C.E. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64 suppl 2 (2005) ii18-ii25
5. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58 (2008) 826-850
6. Gladman D.D. Psoriatic arthritis. Dermatol Ther 17 (2004) 350-363
7. Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 suppl 2 (2005) ii14-ii17
8. Gottlieb A.B., Mease P.J., Mark Jackson J., et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat 17 (2006) 279-287
9. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
10. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
11. Gottlieb A., Korman N.J., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58 (2008) 851-864
12. Cohen M.R., Reda D.J., and Clegg D.O. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 26 (1999) 1752-1756
13. Gladman D.D., Shuckett R., Russell M.L., et al. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 62 (1987) 127-141
14. Torre Alonso J.C., Rodriguez Perez A., Arribas Castrillo J.M., et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30 (1991) 245-250
15. Queiro-Silva R., Torre-Alonso J.C., Tinture-Eguren T., et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 62 (2003) 68-70
16. Kane D., Stafford L., Bresnihan B., et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42 (2003) 1460-1468
17. Durrani K., and Foster C.S. Psoriatic uveitis: a distinct clinical entity?. Am J Ophthalmol 139 (2005) 106-111
18. Paiva E.S., Macaluso D.C., Edwards A., et al. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis 59 (2000) 67-70
19. Gladman D.D., Farewell V.T., Wong K., et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41 (1998) 1103-1110
20. Callis KD, Wong B, Krueger G. Sleep disturbance and medical co-morbidities in patients with psoriasis, psoriatic arthritis, and controls 67th Annual Meeting, March 6-10, 2009, San Francisco, California.
21. Husted J.A., Gladman D.D., Farewell V.T., et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24 (1997) 511-517
22. Zachariae H., Zachariae R., Blomqvist K., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82 (2002) 108-113
23. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
24. Sommer D.M., Jenisch S., Suchan M., et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
25. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
26. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
27. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 47 (2006) 1093-1100
28. Grundy S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5 (2006) 295-309
29. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
30. Brauchli Y.B., Jick S.S., Miret M., et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 160 (2009) 1048-1056 Epub 2009 Feb 4
31. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
32. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
33. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
34. Ena P., Madeddu P., Glorioso N., et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 40 (1985) 199-205
35. Mallbris L., Granath F., Hamsten A., et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006) 614-621
36. Akhyani M., Ehsani A.H., Robati R.M., et al. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 21 (2007) 1330-1332
37. Han C., Robinson Jr. D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006) 2167-2172
38. Tekin N.S., Tekin I.O., Barut F., et al. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007 (2007) 78454 Epub 2006 Dec 27
39. Mallbris L., Ritchlin C.T., and Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8 (2006) 355-363
40. Adult Treatment Panel III, National Cholesterol Education Program Expert Panel on Detection, Evaluation, and and Treatment of High Blood Cholesterol in Adults. Executive Summary. National Institutes of Health (2001), National Heart, Lung, and Blood Institute, Bethesda, MD 140
41. Arnett D.K., McGovern P.G., Jacobs Jr. D.R., et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol 156 (2002) 929-935
42. Ruan H., Miles P.D., Ladd C.M., et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51 (2002) 3176-3188
43. Zuliani G., Volpato S., Ble A., et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: The InChianti study. Atherosclerosis 192 (2007) 384-390
44. Farshchian M., Zamanian A., Farshchian M., et al. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 21 (2007) 802-805
45. Shapiro J., Cohen A.D., David M., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
46. Cohen A.D., Gilutz H., Henkin Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 87 (2007) 506-509
47. Cohen A.D., Dreiher J., Shapiro Y., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 22 (2008) 585-589
48. Cohen A.D., Sherf M., Vidavsky L., et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 216 (2008) 152-155
49. Lillioja S., Mott D.M., Howard B.V., et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318 (1988) 1217-1225
50. Ucak S., Ekmekci T.R., Basat O., et al. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20 (2006) 517-522
51. Reynoso-von Drateln C., Martinez-Abundis E., Balcazar-Munoz B.R., et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48 (2003) 882-885
52. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
53. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
54. Huerta C., Rivero E., and Rodriguez L.A. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143 (2007) 1559-1565
55. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
56. Jiang J., and Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 6 (2008) 1-7
57. McDonald C.J., and Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 99 (1978) 469-475
58. Pearce D.J., Morrison A.E., Higgins K.B., et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 16 (2005) 319-323
59. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
60. Chodorowska G., Wojnowska D., and Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 18 (2004) 180-183
61. Nielsen H.J., Christensen I.J., Svendsen M.N., et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51 (2002) 563-567
62. Vanizor Kural B., Orem A., Cimsit G., et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 328 (2003) 71-82
63. Vanizor Kural B., Orem A., Cimsit G., et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 332 (2003) 23-30
64. Ridker P.M., Rifai N., Cook N.R., et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
65. Strober B., Teller C., Yamauchi P., et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159 (2008) 322-330
66. Glynn R.J., MacFadyen J.G., and Ridker P.M. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 55 (2009) 305-312
67. Ludwig R.J., Herzog C., Rostock A., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
68. Kimhi O., Caspi D., Bornstein N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36 (2007) 203-209
69. Dreiher J., Weitzman D., Shapiro J., et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 159 (2008) 956-960
70. Gelfand J.M., Azfar R., Shin D., et al. Incidence of stroke in patients with psoriasis: a population-based study. J Invest Dermatol 128 (2008) 81
71. Kaye J.A., Li L., and Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008) 895-902
72. Margolis D., Bilker W., Hennessy S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol 137 (2001) 778-783
73. Gelfand J.M., Shin D.B., Neimann A.L., et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
74. Baecklund E., Askling J., Rosenquist R., et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16 (2004) 254-261
75. Jeffes III E.W., Lee G.C., Said S., et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol 105 (1995) 733-738
76. Mahmoud F., Abul H., al Saleh Q., et al. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis. J Dermatol 26 (1999) 428-433
77. Krueger J.G., and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 (2005) ii30-ii36
78. Boffetta P., Gridley G., and Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117 (2001) 1531-1537
79. Olsen J.H., Moller H., and Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 27 (1992) 716-722
80. Frentz G., and Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140 (1999) 237-242
81. Nijsten T.E., and Stern R.S. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 121 (2003) 252-258
82. Lindelof B., Sigurgeirsson B., Tegner E., et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 141 (1999) 108-112
83. Behnam S.M., Behnam S.E., and Koo J.Y. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 4 (2005) 189-194
84. Prodanovich S., Ma F., Taylor J.R., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267
85. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
86. Jacobsson L.T., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
87. Naranjo A., Sokka T., Descalzo M.A., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10 (2008) R30
88. Georgiadis A.N., Voulgari P.V., Argyropoulou M.I., et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38 (2008) 13-19
89. Stern R.S., Nichols K.T., and Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 336 (1997) 1041-1045
90. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
91. Franklin J., Lunt M., Bunn D., et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65 (2006) 617-622
92. Ganguly S. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. Am J Clin Dermatol 10 (2009) 125-126
93. Hurley M.Y., George M.N., Leonardi C.L., et al. A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists. Diagn Pathol 3 (2008) 13
94. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5 (2006) 197-209
95. Katz H.I., Waalen J., and Leach E.E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41 (1999) S7-S12
96. Tilling L., Townsend S., and David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 26 (2006) 55-62
97. Lindsay K., and Gough A. Psoriatic arthritis, methotrexate and the liver-are rheumatologists putting their patients at risk?. Rheumatology (Oxford) 47 (2008) 939-941
98. Kimball A.B., Gladman D., Gelfand J.M., et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 (2008) 1031-1042
99. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150 (2009) 188-193
100. Gottlieb A., Korman N.J., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58 (2008) 851-864
101. Boehncke S., Thaci D., Beschmann H., et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 157 (2007) 1249-1251
102. Cohen A.D., Gilutz H., Henkin Y., et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 87 (2007) 506-509
103. Cohen A.D., Dreiher J., Shapiro Y., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 22 (2008) 585-589
104. Gisondi P., Tessari G., Conti A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73